Momentum Is Back At Cipla In Q2

However, The Indian Firm Has Seen Albuterol Delayed In US

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.

Arrows_Coloured
Cipla Reports Strong Recovery In Q2 • Source: Shutterstock

More from Earnings

More from Business